This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Drugs Fut (1994) 19(1):70-71
Drugs Fut (1991) 16(1):19-22
Morii M, Takata H, Fujisaki H, Takeguchi N (1990) Biochem Pharmacol 39:661–667
Morii M, Hamatani K, Takeguchi N (1995) Biochem Pharmacol 49:1729–1734
Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E (1995) Aliment Pharmacol Ther 9:363–378
Tomiyama Y, Morii M, Takeguchi N (1994) Biochem Pharmacol 48:2049–2055
Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N (1991) Biochem Pharmacol 42:321–328
Hirai M, Azuma T, Ito S, Kato T, Kohli Y (1995) J Gastroenterol 30:461–464
Clarke ECG (1969) Isolation and Identification of Drugs, The Pharmaceutical Press, London, S. 534
Schnider O, Grüssner AA (1949) Helv Chim Acta 32:821–829
Moffat AC (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, London, S. 956
Steal AH, Gill R, Wright T, Gibbs JP et al. (1982) Analyst 107:1106–1168
Braga PC, Fossati A, Vemercati MG, Caputo R, et al. (1994) Dextrorphan and dextromethorphan: comparative antitussive effects on guinea pigs. Drugs Exp Clin Res 20:199–203
Drugs Fut (1986) 11:387-388
Carrupt PA, Tsai RS, El Tayar N, De Paulis T, Hoegberg T (1991) Helv Chim Acta 74(5):956–968
Nilsson LB (1990) J Chromatogr 506:253–264
Adam MJ, Grierson JR, Jivan S (1989) Appl Radiat Isot 40:91–92
Pike VW, Kensett MJ, Turton DR, Waters S, Silvester DJ (1990) Appl Radiat Isot 41:483–492
Brithish Isles Raclopride study group (1992) A double-blind comparison of raclopride and haloperidol in the acute phase of schizophenia. Acta Psychiat Scand 86:391–398
Patoia L, Berchicci P (1990) Drug Fut 15:689–694
Cavalleri B, Pagani H, Volpe F, Selva E, Parenti F (1984) J Antibiot 37:309–317
Kurz M, Guba W (1996) Biochem 35:12570–12575
Sommer EA, Reynolds PE (1990) Antimicrob Agents Chem 34:413–419
Somner EA, Reynolds PE (1990) Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother 34:413–419
O’Hare MD, Ghosh G, Felmingham D, Grüneberg RN (1990) In vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial. J Antimicrob Agents Chemother 25:217–220
Biavasco F, Manso E, Varaldo PE (1991) In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Ag Chemother 35:195–197
Johnson CC, Taylor S, Pitsakis P, May P, Levison ME (1992) Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother 36:2342–2345
Collins LA, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC (1993) In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 37:1364–1366
Mar 31, S. 267
Drug Fut (1995) 20:480-482
Pipkin GA, Wood JR (1997) Drug Today 33:431–451
Sadler PJ, Sun H (1995) J Chem Soc, Dalton Trans:1395-1401
Lacey LF, Frazer NM, Keene ON et al. (1994) Eur J Clin Pharmacol 47:177–180
Tillman LA, Drake FM, Dixon JS et al. (1996) Aliment Pharmacol Ther 10:459–467
Syntex, zit. nach CA 102:166777 (U.S.A.), EP 126449 Al 28.11.1984
Richter, zit. nach CA 117:48614, Gedeon EP 483932 Al 06.05.1992
Lodge JPA, Lam FT, Perry SL, Giles GR (1990) Transplantation 50(5):755–759
Delee E (1987) Chromatographia 24:357–359
McCormack JG, Barr RL, Wolff AA, Lopaschuk GD (1996) Ranolazine stimulates glucose oxidation in normioxic, ischemic, and reperfused ischemic rat hearts. Circulation 93:135–142
Gralinski MR, Black SC, Kilgore KS, Chou AY, et al. (1994) Cardioprotetive effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res 28:1231–1237
Allen TJ, Chapman RA (1996) Effects of ranolazine on L-type clacium channel currents in guinea-pig single ventricular myocytes. Br J Pharmacol 118:249–254
Wyatt KM, Skene C, Veitch K, Hue L, et al. (1995) The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochem Pharmacol 50:1599–1606
Jain D, Dasgupta P, Hughes LO, Lahiri A, et al. (1990) Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Eur J Clin Pharmacol 38:11–114
Cocco G, Rousseau MF, Bouvy T, Cheron P, et al. (1992) Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 20:131–138
Thadani U, Ezekowitz M, Fenney L, Chiang YK (1994) Double-blind efficacy and safety study of a novel antiischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation 90:726–734
Uchida M, Tabusa F, Komatsu M, Kanbe T, Nakagawa K (1985) Chem Pharm Bull 33:3775–3786
Otsubo K, Morita S, Uchida M, Yamasaki K, Kanbe T, Shimizu T (1991) Chem Pharm Bull 39:2906–2909
Monographie (1988) Drugs Fut 13:959–961
Shioya Y, Shimizu T (1988) J Chromatogr 434:283–287
Yamasaki K, Ishiyama H, Imaizumi T, Kanabe T, Yabuuchi Y (1989) Japan J Pharmacol 49:441–448
Kleine A, Kluge S, Peskar BM (1993) Dig Dis Sci 38:1441–1449
Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K (1992) Arzneim-Forsch/Drug Res 42:1462–1466
Ogino K, Hobara T, Ishiyama H, Yamasaki K, Kobayashi H, Izumi Y, Oka S (1992) Eur J Pharmacol 212:9–13
Drugs Fut (1994) 19(12):1088-1092
Feldman PL, James MK, Brackeen MF, Johnson MR, Leighton HJ (Glaxo Inc.) n-Phenyl-N-(4-piperidinyl)amides useful as analgetics, EP 383579, JP 90300167, US 5019583
Feldman PL, James MK, Brackeen MF, Bilotta JM, Schuster SV, Lahey AP, Lutz MW, Johnson MR, Leighton HJ; Design, synthesis ans pharmacological evaluation of ultra-short-to long-acting opoid analgetics. (1991) J Med Chem 348(7):2202–2208
Glass PS, Hardman D, Kamiyama Y, Quill TJ, Marton G, Donn KH, Grosse CM, Herrmann D (1993) Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth Analg 77:1031–1040
Egan TD, Minto CF, Hermann DJ, Barr J, Muir KT, Shafer SL (1996) Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 84:821–833
Lemmens HJ (1995) Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia. Clin Pharmacokinet 29:231–242
Westmoreland CL, Hoke JF, Sebel PS, Hug CC JR, Muir KT (1993) Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 79:893–903
Egan TD, Lemmens HJ, Fiset P, Hermann DJ, Muir KT, Stanski DR, Shafer SL (1993) The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 79:881–892
Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM (1995) Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil. J Pharmacol Exp Ther 274:34–39
Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw LL, Peng AW, Jamerson Bd (1995) Initial clinical experience with remifentanil, a new opioid metabolized by esterases. Anesth Analg 81:619–623
Schraag S, Georgieff M (1995) Intravenous anesthesia-current aspects. Anaesthesiol Intensivmed Notfallmed Schmerzther 30:469–478
Lang E, Kapila A, Shlugman D, Hoke JF, Sebel PS, Glass PS (1996) Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology 85:721–728
Hogue CW, Bowdle TA, O’Leary C, Duncalf D, Miguel R, Pitts M, Streisand J, Kirvassilis G, Jamerson B, McNeal S, Battenhorst R (1996) A multicenter evaluation of total intraveous anesthesia with remifentanil and propofol for elective inpatient surgery. Anesth Analg 83:279–285
Fragen RJ (1995) Implications of the use of remifentanil on patient outcomes. Eur J Aneaesthesiol suppl 10:75–76
Sebel PS, Hoke JF, Westmoreland C, Hug CCJ, Muir KT, Sziam F (1995) Histamine concentrations and hemodynamic responses after remifentanil. Anesth Analg 80:990–993
Himmelmann A, Bergbrant A, Svensson A, Hansson L, Aurell M (1996) Remikiren (Ro 42-5892) — an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the reinin-angiotensin-system. Am J Hypertension:517-522
Johnston CI (1990) Biochemistry and pharmacology of the renin-angiotensin system. Drugs 39:21–31
Van den Meiracker AH, Admiraal PJJ, Derkx FHM, Kleinbloesem C, Manin’t Veld AJ (1990) Comparison of Blood pressure and angiotensin responses to the renin inhibitor RO 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. J Hypertension 11:831–838
Camenzind E, Nussberger J, Juillerat L, Munafo A, Fischli W (1991) Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans. J Cardiovasc Pharmacol 18:299–307
Weber C, Birnböck H, Leube J, Kobrin I, Kleinbloesem CH (1993) Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. Br J Clin Pharmacol 36:547–554
Viskoper RJ, Charlon V, Laszt A, Yosefi C, Bock J (1994) Time dependency of the antihypertensive efficacy of the new renin inhibitor RO 42-5892. J Human Hypertension 8:133–136
Van Paassen P, de Zeeuw D, de Jong PE. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension. J Cardiovasc Pharmacol 26:39-45
Kobrin I, Viskoper RJ, Laszt A, Bock J, Weber C (1993) Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertension 6:349–356
Kleinbloesem CH, Weber C, Fahrner E, Dellenbach M, Welker H (1993) Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin Phamacol Ther 53:585–592
Widman M, Nilsson LB, Bryske B, Lundström J (1993) Arzneim Forsch 43:287–297
Nilsson LB (1990) J Chromatogr 526:139–150
Florvall GL, Oegren SO (1979) CA 1109484 A2, zit. nach CA (1982) 96:68629
Pettersson C, Gioeli C (1993) Chirality 5:241–245, zit. nach CA (1994) 120:207658
Haupt D, Pettersson C, Westerlund D (1993) Chirality 5:224–228, zit. nach CA (1994) 120:207657
Kerwin R, Taylor D (1996) New antipsychotics. A review of their current status and clinical potential. CNS Drugs 6:71–82
Owens DGC (1996) Adverse effects of antipsychotic agents. Drugs 51:896–930
King FD, Hadley MS, Joiner KT, Martin RT, Sanger GJ, Smith DM, Smith GE, Smith P, Turner DH, Watts EA (1993) J Med Chem 36:683–689
Collin S, Moureau F, Quintero MG, Vercauteren DP, Evrard G, Durant F (1995) J Chem Soc Perkin Trans II:77–84
Robertson CS, Evans DFR, Hicks F, Atkinson M (1988) Aliment Pharmacol Ther 2:501–506
Staniforth DH, Pennick M (1990) Eur J Clin Pharmacol 38:161–164
Craig DA, Clarke DE (1991) Br J Pharmacol 102:563–564
Sanger GJ (1987) Br J Pharmacol 91:77–87
Cooper SM, McClelland CM, McRitchie B, Turner DH (1986) Br J Pharmacol 88:383P
Mackie AD, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR (1991) Aliment Pharmacol Ther 5:135–142
Knoll & Co. (1899) DRP 103.857
Clarke EGC (1986) Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S. 959
Beilstein E4 VI, S. 5.672
Hoshi A, Castañer J (1994) Drugs Fut 19:122–124
Dormoy JR, Heymes A (1993) Tetrahedron 49:2915–2938
Bisagni E, Ducrocq C, Lhoste JM, Rivalle C, Civier A (1979) J Chem Soc Perkin Trans 1:1706–1711
Ducrocq C, Wendling F, Tourbez-Perrin M, Rivalle C et al. (1980) J Med Chem 23:1212–1216
Langdon SP, Hendriks HR, Braakhuis BJ, Pratesi G, Berger DP, Fodstad O, Fiebig HH, Boven E (1994) Preclinical phase II studies in human tumor xenografts: a european multicenter follow-up study. Ann Oncol 5(5):415–422
Kattan J, Durand M, Droz JP, Mahjoubi M, Marino JP, Azab M (1994) Phase I study of retelleptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule. Am J Clin Oncol 17(3):242–245
ABDA, Pharmazeutische Stoffliste
Deutsch Apoth Ztg (1993) Neue Arzneimittel 10
Desnoyers PC, Samama MM (1995) Pharmakokinetics and metabolism of reviparin. Drugs Today 31(Suppl. D):61–72
Kakkar W, Cohen AT, Mohamed MS (1996) Patients at risk of venous thromboembolism — clinical results with reviparin. Thromb Res 81:39–45
Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A (1996) Preclinical studies on a low molecular weight heparin. Thromb Res 81:S1–S27
Klöcking HP (1994) Influence of pentosan polysulfate sodium compared with other polyanion compounds on the t-PA and PAI-1 activity. Perfusion 7(Suppl. 2) 7:32–38
Pindur G, Köhler M, Wenzel E (1989) Study of new low molecular weight heparin (LU 47311) administered to healthy volunteers. Folia Haematol (Leipzig) 116:859–866
Andrassy K, Eschenfelder V, Koderisch J, Weber E (1994) Pharmacokinetics of Clivarin® a new low molecular weight heparin in healthy volunteers. Thromb Res 73:95–108
Cohen AT, Mohamed MS, Kakkar VV (1995) The clinical experience of reviparin in the prevention of deep vein thrombosis. Drugs Today 31(Suppl.D):5–9
Boneu B (1993) An international multicenter study: Clivarin® in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin® Assesment Group. Blood Coagul Fibrinolysis 4(Suppl.1):S21–S22
Kakkar VV (1993) Efficacy and safety of Clivarin® and other LMWHs in general surgery: A meta-analysis. Blood Coagul Fibrinolysis 4(Suppl.1):S23–S27
Kakkar VV, Boeckl O, Boneu B, Bordenave L, Brehm OA, Brucke P, Coccheri S, Cohen AT, Galland, Haas S, Jarrige J, Koppenhagen K, Le Querrec A, Parraguette E, Prandoni P, Roder JD, Roos M, Ruschemeyer C, Siewert JR, Vinazzer J, Wenzel E (1997) Efficacy and safety of a low-molecular-weight heaprin and standard unfractionated heparin in prophylaxis of postoperative venous thromboembolism: A Europeen multicenter trial. World J Surg 21:2–8
Planés A (1995) Reviparin in elective hip surgery. Drugs Today 31(Suppl. D):45–48
Planés A, Vochelle N, Chevret S, Fagola M, Bellaud M (1993) Dose-finding studies of reviparin in elective hip surgery. Semin Thromb Haemost 19(Suppl. 1):44–48
Planés A (1993) Comparison of antithrombotic efficacy and haemorrhagic side-effect of Clivarin® versus Enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis 4(Suppl.1):S33–S35
Preisack M, Karsch KR (1996) Low molecular weight heparin in prevention of restenosis after PTCA. Thromb Res 81(Suppl.2):S53–S59
Karsch KR (1995) Prevention of restenosis after PTCA with reviparin. Drugs Today 31(Suppl.D):49–60
Schmid KM, Preisack M, Voelker W, Sujatta M, Karsch KR (1993) First clinical experience with low molecular weight heparin LU 47311 (Reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Haemost 19(Suppl. 1):155–159
Preisack M, Karsch KR (1993) Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty. Blood Coagul Fibrinolysis 4(Suppl.1):S55–S58
Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (1996) Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. J Am Coll Cardiol 28:1437–1443
Samama MM, Desnoyers PC (1995) Low molecular weight heparins: an overview. Thrombosis 5:95–106
Andrassy K (1993) Low molecular weight heparin and haemodialysis: Neutralisation by protamine chloride. Blood Coagul Fibrinolysis 4(Suppl. 1):S39–S43
Baumelou A, Singlas E, Petitclerc T, Desmichels D, Jacobs C, Soria J (1994) Pharmacokinetics of a low molecular weight heparin (reviparine) in haemodialysed patients. Nephron 68:202–205
Kakkar VV (1996) Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis. Thromb Res 81(Suppl. 2):S75–S77
Andrassy K, Eschenfelder V (1996) Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 81:S29–S38
Frydman A (1996) Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacocinetics and metabolism in humans. Haemostasis 26(Suppl.2):24–38
Andrassy K, Eschenfelder V, Weber E (1994) Neutralisation of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride. Thromb Res 73:85–93
Knoll Investigator’s Brochure Clivarine® (1996) Knoll AG, Ludwigshafen, Edition 7/96,pp13-14
Klöcking HP, Jelinek A, Klöcking R (1998) The cytotoxicity of sulfated carbohydrates with anticoagulated and profibrinolytic properties. Pharm Pharmacol Lett 8:72–74
Csupor L (1971) Arch Pharm 304:32 ff
Negwer M (1994) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin, S. 8386
Bironsite D, Ollinger K (1997) Chem Biol Interact 103:35–50
Spencer CM, Wilde MI (1997) Drugs 53:98–106
Yael T, Yamauchi K, Kuwano S (1997) J Pharm Pharmacol 49:22–25
Witkowski JT, Robins RK, Sidwell RW, Simon LN (1972) J Med Chem 16:1150–1154
Witkowski JT, Robins RK, Khare GP, Sidwell RW (1973) J Med Chem 16:935–937
Paroni R, Sirtori CR, Borghi C, Galli KM (1987) J Chromatogr 420:189–196
Smith RHA, Gilbert BE (1987) J Chromatogr 414:202–210
Granich GG, Krogstad DJ, Connor JD, Desrochers KL, Sherwood C (1989) Antimicrob Agents Chemother 33:311–315
Hayden FG (1995) Virustatic agents, Ribavirin. In: Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases 4th edition. Churchill Livingstone New York: 430-431
Wray SK, Gilbert BE, Noall MW, Knight V (1985) Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 5:29–37
Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Ten Eyck LG, Hall WJ (1983) Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 308:1443–1447
Groothuis JR, Woodin KA, Katz R, Robertson AD, McBride JT, Hall CB, McWilliams BC, Lauer BA (1990) Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr 117:792–798
Smith DW, Frankel LR, Mathers LH, Tang AT, Araigno RL, Prober CG (1991) A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N. Engl. J Med 325:24–29
NN (1997) Virazole. Informationsmaterial des Herstellers (ICN Pharmaceuticals, D-37269 Eschwege) (Online:http://www.icnpharm.com/pharma/insert.htm)
Connor J (1990) Ribavirin pharmacokinetics. Pediatr Infect Dis J 9(9 Suppl):S91–S92
Fa. Hoffmann-La Roche (1970) Vitamin-Compendium, Basel, S. 98-104
Friedrich W (1987) Handbuch der Vitamine, Urban & Schwarzenberg, München Wien Baltimore, S. 261–304
Pharmeuropa (1994) 6:268-270
Hsu HC (1978) T’ai-wan Yao Hsueh Tsa Chih 30:20–29, zit. nach CA (1979) 90:174583
Adanyaeva RV, Demisova LY, Borovikova ON, Berezovskii VM (1967) Khim Farm Zh 1:16–19, zit. nach CA (1967) 67:25380
Maeda Y, Owada K, Yamamoto M, Sano S, Masui T, Kitada Y (1990) Iyakuhin Kenkyu 21:444–448, zit. nach CA (1990) 113:198102
Mar 31, S. 1383
Schoenen J, Lenaerts M, Bastings E (1994) Cephalgia 14:328–329
Mar 31, S. 1748
Freyne EJ, Raeymaekers AHM, Venet MG, Sipido VK, De Clerck F (1990) Drug Fut 15:463–466
De Clerck F, Beetens J, de Chaffoy, de Courcelles D, Freyne E, Janssen PA (1989) R68 070: thromboxane A2 synthetase inhibiton und thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. I. Biochemical profile in vitro. Thromb Haemost 61:35–42
De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PA (1989) R 86 070: thromboxane A2 synthase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. II Pharmacological effects in vivo and ex vivo. Thromb Haemost 61:43–49
Hoet B, Deckmyn H, Arnout J, Vermylen J (1990) Pharmacological manipulation of the thromboxane pathway in blood platelets. Blood Coagul Fibrinolysis 1:225–233
de Chaffoy de Courcelles D, De Clerck F (1990) Effect of thromboxane A2 synthetase inhibition, single and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets. Eur J Pharmacol 188:161–169
Vanden Bossche H, Willemsens G, Bellens D, Janssen PA (1992) Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis. Biochem Pharmacol 43:739–744
Heylen L, De Clerck F, Somers Y, Leysen JE (1991) Thromboxane A2/prostaglandin endoperoxide (TXA2/ PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor-TXA2/ PG-END receptor antagonist. Blood Coagul Fibrinolysis 2:617–621
Bourgain RH, Andries R, Decuyper K, De Clerck F (1991) Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptor by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries. J Lipid Mediat 3:3–11
Verheyen A, Lauwers F, Vlaminckx E, De Clerck F (1989) Differential vasoreactivity to the thromboxane A2 mimic U-46619 of collateral and normal peripheral blood vessels in situ perfused rat hindquarters. Blood Vessels 26:165–176
Janssen WJ, Cools FJ, Hoskens LA, Van Nueten JM (1990) Effect of ridogrel on vascular contractions caused by vasoactive substances released during platelet activation. Thromb Haemost 64:91–96
Vandeplassche G, Hermans C, Van de Water A, Xhonneux R, Wouters L, Van Ammel K, De Clerck F (1991) Differential effects of thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries. Circ Res 69:313–324
Vandeplassche G, Hermans C, Somers Y, Van de Werf F, de Clerck F (1993) Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase. J Am Coll Cardiol 21:1269–1279
Hoet B, Arnout J, Vermylen J (1989) R68070, a combined thromboxane/endoperoxide receptor antagonist (TRA) and thromboxane synthase inhibitor (TSI), prolongs the bleeding time more than aspirin in man. Prog Clin Biol Res 301:537–577
Weber C, Beetens JR, Tegtmeier F, Van Rooy P, Vercammen E, Wouters L, De Clerck F (1992) Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration in man. Thromb Haemost 68:214–220
Ritter JM, Barrow SE, Doktor HS, Stratton PD; Edwards JS, Henry JA, Gould S (1993) Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension. Hypertension 22:197–203
De Cree J, Geukens H, Gutwirth P, De Clerck F, Vercammen E, Verhaegen H (1993) The effect of a combined administration of ridogrel and ketanserin in patients with intermittens claudication. Int Angiol 12:59–68
Timmermans C, Vrolix M, Vanhaecke J, Stammen F, Piessens J, Vercammen E, De Geest H (1991) Ridogrel in setting of percutaneous transluminal coronary angioplasty. Am J Cardiol 68:463–466
van der Wieken LR, Simoons ML, Laarman GJ, Van den Brand M, Nijssen KM, Dellborg M, Hermens W, Vrolik W (1995) Ridogrel as an adjunct to thrombolysis on acute myocardial infarction. Int J Cardiol 52:125–134
Tranchesi B, Pileggi F, Vercammen E, Van de Werf F, Verstraeten M (1994) Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin. Eur Heart J 15:660–664
Cricchio R, Arioli V (1976) Ger Offen 2,608,218; zit. nach CA 86:43757
Riva E, Merati R, Cavenaghi L (1991) J Chromatogr 553:35–40
Vékey K, Edwards DMF, Zerilli LF (1989) J Chromatogr 474:317–327
Marchi E, Montecchi L, Venturini AP, Mascellani G, Brufani M, Cellai L (1985) J Med Chem 28:960–963
Dampier MF, Chen CW, Whitlock HW (1976) J Am Chem Soc 98:7064–7069
Bellomo P, Marchi E, Mascellini G (1981) J Med Chem 24:1310–1314
Corti P, Savini L, Celesti L, Ceramelli G, Montecchi L (1992) Pharm Helv Acta 67:76–79
Gillis JC, Brogden RN (1995) Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49:467–484
Drugs Fut (1986) 11(6):470-471
Bousquet P (1995) Imidazoline receptors: from basic concepts to recent development. J Cardiovasc Pharmacol 26(Suppl 2):S1–S6
van Zwieten PA (1995) Central imidazoline receptors as a target for centrally acting antihypertensive drugs. Pharm World Sci 17:186–190
Head GA (1995) Importance of imidazoline receptors in the cardiovascular actions of centrally acting antihypertensive agents. Ann NY Acad Sci 763:531–540
Schafer SG, Kaan EC, Christen MO, Low Kroger A, et al. (1995) Why imidazoline receptor modulator in the treatment of hypertension? Ann NY Acad Sci 763:659–672
Boucher M, Dubar M, Chassaing C, Vivet P, et al. (1994) Cardiac electrophysiological effects of rilmenidine, a novel antihypertensive agent, in the conscious dog: comparison with clonidine. Life Sci 54:PL381–PL387
Szabo B, Urban R (1995) Mechanism of sympathoinhibition by imidazolines. Ann NY Acad Sci 763:552–565
Hauser W, Gutting J, Nguyen T, Dominiak P (1995) Influence of imidazolines on catecholamine release in pithed spontaneously hypertensive rats. Ann NY Acad Sci 763:573–579
Gargalidis Moudanos C, Parini A (1995) Selectivity of rilmenidine for Il-imidiazoline-binding sites in rabbit proximal tubule cells. J Cardiovasc Pharmacol 26(Suppl 2):S59–S62
Kline RL, van der Mark J, Cechetto DF (1994) Natriuretic effect of rilmenidine in anesthetized rats. Am J Cardiol 74:20A–24A
Evans RG, Anderson WP (1995) Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2-adrenoceptors. Br J Pharmacol 116:1557–1570
Fletcher AE, Beevers DG, Dollery CT, Wilkinson R, et al. (1991) The effects of two centrally-acting anti-hypertensive drugs on the quality of life. Eur J Clin Pharmacol 41:397–400
Pillion G, Fevrier B, Codis P, Schutz D (1994) Long-term control of blood pressure by rilmenidine in high-risk populations. Am J Cardiol 74:58A–65A
Licata G, Scaglione R, Guillet C, Capuana G, et al. (1993) Double-blind controlled study of rilmenidine versus hydrochlorothiazide in mild hypertension: clinical and renal haemodynamic evaluation. J Hum Hypertens 7:153–157
Luccioni R (1995) Evaluation pharmaco-epidemiologique de la rilmenidine chez 18235 hypertendus. Presse Med 24:1857–1864
Fiorentini C, Guillet C, Guazzi M (1989) Étude multicentrique en double aveugle comparant la rilmenidine 1 mg et l’hydrochlorothiazide 25 mg chez 244 patients. Arch Mal Coeur Vaiss 82:39–46
Trimarco B, Morisco C, Sarno D, Lovino G, et al. (1995) Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass. J Cardiovasc Pharmacol 26(Suppl 2):S29–S33
Pelemans W, Verhaeghe J, Creytens G, Coupez G, et al. (1994) Efficacy and safety of rilmenidine in elderly patients — comparison with hydrochlorothiazide. The Belgian Multicentre Study Group. Am J Cardiol 74:51A–57A
Genissel P, Bromet N (1989) Pharmacokinetics of rilmenidine. Am J Med 87:18S–23S
Aparicio M, Dratwa M, el Esper N, Fillastre JP, et al. (1994) Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. Am J Cardiol 74:43A–50A
Krentz AJ, Evans AJ (1998) Selective imidazoline receptor agonists for metabolic syndrome. Lancet 351:152–153
Lins RL, Daelemans R, Dratwa M, Verbeelen D, et al. (1989) Acceptability of rilmenidine and long term surveillance of plasma concentrations in hypertensive patients with renal insufficiency. Am J Med 87:41S–45S
Braga PC, Dal Sasso M, Maci S, Piatti G, Dannhorn DR, Bohn M (1995) Arzneim-Forsch/Drug Res 45(I):84–87
Raether W, Hänel H (1990) Rilopirox — a new hydroxypyridone antifungal with fungicidal properties. Mycoses 33:191–202
Drugs Fut (1994) 19:920-922
Jimonet P, Audiau P, Barreau M, Mignani S (1993) Heterocycl 36:2745–2752
Produktmonographie der Fa. Rhone-Poulenc Rorer
Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 330:585–691
Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J (1994) Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport. 5:1012–1014
Doble A, Hubert JP, Blanchard JC (1992) Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-(3H)aspartate release from cultured cerebellar granule cells. Neuroscience Letters. 140:251–254
Hubert JP, Delumeau JC, Glowinski J, Premont J, Doble A (1994) Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Brit J Pharmacol. 113:261–267
Rowland LP (1994) Amyotrophic lateral sclerosis. Current Opinion in Neurology. 7:310–315
Samuel D, Blin O, Dusticier N, Nieoullon A (1992) Effects of riluzole (2-amino-6-trifluoromethoxy benzothiazole) on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity. Fundam Clin Pharmacol 6:177–184
Benedict JJ, Perkins CM; AU 85513534, EP 186405, ES 8707543 (1993) Drugs Fut 18(7):605-608
Wellcome Foundation Ltd. Jap Pat 8064585; zit. nach CA (1985) 94:4042
Vitté C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324–2333
Fleisch H (1991) Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919–944
Roux C, Ravaud P, Cohen-Solal M (1994) Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 15:41–49
Brown HP, Kylstra JW, Bekker PJ (1994) Risedronate in Paget’s disease: preliminary results of a multicenter study. Sem Arthritis Rheum 23:272
Delmas PD, Balena R, Confravreux E (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind placebo-controlled study. J Clin Oncol 15:955–962
Reasner CA, Stone MD, Hosking DJ (1993) Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. Clin Endocrinol Metab 77:067–1071
Watts NB (1994) Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 20:717–734
Fleisch H (1994) Bisphosphonates: pharmacology. Sem Arthritis Rheum 23:261–262
Kennis LEJ, Vandenberk J (1986) Eur Pat Appl EP 196132, zit. nach CA (1987) 160:67292x
Woestenborghs R, Lorreyne W, van Rompaey F (1992) J Chromatogr 582:223–230
le Moing JP, Edouard S, Levron JC (1993) J Chromatogr 614:333–339
Buckley PF (1997) New dimensions in the pharmacological treatment of schizophrenia and related psychoses. J Clin Pharmacol 37:363–378
Jacobsen FM (1995) Risperidone in the treatment of affective illness and obsessive — compulsive disorder. J Clin Psychiat 56:423–429
Kerwin R, Taylor D (1996) New Antipsychotics. A review of their current status and clinical potential. CNS Drugs 6:71–82
Umbricht D, Kane JM (1996) Medical complications of new antipsychotic drugs. Schizophrenia Bull 22:475–483
Peuskens J (1995) Risperidon in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Brit J Psychiat 166:712–733
Drugs Fut (1986) 11(5):391-393
Marsden CA (1990) The pharmacology of new anxiolytics acting on 5-HT neurones. Postgrad Med J 66(Suppl 2):S2–S6
Bersani G (1991) 5-HT2-receptor antagonism in dystymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 83:244–248
Wagner B, Schneider B, Blöchl-Daum B, Speiser W, et al. (1990) Effect of ritanserin, a 5-hydroxytryptamine2-receptor antagonist, on platelet function and thrombin generation at the site of plug formation in vivo. Clin Pharmacol Ther 48:419–423
Stott DJ, Saniabadi AR, Lowe GDO, Ball SG (1988) The effects of the 5-HT2-antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension. Eur J Clin Pharmacol 35:132–129
Bedeschi A, Cabri W, Marchi M, Perrone E (Farmitalia Carlo Erba) GB 9006114.4; zit. nach Drugs Fut (1991) 16:313-316
Battistini C, Scarafile C, Foglio M, Franceschi G (1984) Tetrahedron Lett 25:2395–2398
Altamura M, Cesti P, Francalanci F, Marchi M, Cambiaghi S (1989) J Chem Soc Perkin Trans I, 1225–1229
Franceschi g, Bedeschi A, Rizzo V, Vigevanni A (1993) Bioorg Med Chem Lett 3:2333–2336
Efthymiopoulos C, Strolin Benedetti M, Sassella D, Boobis A, Davies D (1992) Antimicrob Ag Chemother 36(9):1958–1963
Saathoff A, Lode H, Hampel B, Deppermann KM, Borner K, Koeppe P (1990) Antimicrob Ag Chemother 34(6):1001–1006
Boersma WG, Puister SMT, van Altena R, de Vries-Hospers HG, Molinari M, Koeter GH (1994) Antimicrob Ag Chemother 38(4):872–875
Norrby SR, Dornbusch K, Molinari M, Sassella D, Atti E, Gefvert O, Zador R, Petroccione A, Cairoli C, Fransson G, Denstedt-Stigzelius I, Bakall A, Olsson E, Wiberg PO, Babra M, Gaseb M, Pavek E, Johansson S, Bergstad B, von Kraemer S, Thorell NI, Grundestam I, Forsberg G, Almqvist G, Tilling B, Gnarpe H, Schwan A, Sörén L (1995) Clin Infect Dis 20:507–513
Livingstone D, Gill MJ, Wise R (1995) J Antimicrob Chemother 35(1):1–5
Norrby SR, Burman LA, Sassella D, Corigli R, Cassinelli G, Franceschi G, Dornbusch K (1990) J Antimicrob Chemother 25:371–383
Lovering AM, MacGowan AP, Lewis DH, Reeves DS (1992) J Antimicrob Chemother 29:179–185
Webberley JM, Wise R, Andrews JM, Ashby JP, Wallbridge D (1988) J Antimicrob Chemother 21:445–450
Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE (1992) Clin Infect Dis 15(Suppl 1):216–227
Saito A, Kawakami Y, Yamaguchi E, Koba H, Abe S, Ohmichi M, Hiraga Y, Kikuchi K, Ohsaki Y, Matsumoto H, Inoue H, Yoshida M, Mouri T, Kobayashi H, Ito T, Bando T, Takeuchi K, Hirano H, Tanifuji Y, Tanno Y, Kirato K, Takahashi M, Sakamoi M, Nakashima M; et al. (1996) Jap J Antibiotics 49(3):219–249
NN (1993) Drugs Fut 18:373
Angerbauer R, Fey P, Hübsch W, Philipps T, Bischoff H, Petzinna D, Schmidt D, Thomas G (Bayer AG) EP 325139, US 5006530, US 5169857 und Angerbauer R, Fey P, Hübsch W, Philipps T, Bischoff H, Petzinna D, Schmidt D, Thomas G (Bayer AG) EP 491226, US 5177080; beide zit. nach Lit. 2
Angerbauer R, Bischoff H, Steinke W, Ritter W (1994) Drugs Fut 19:537–541
Angerbauer R, Bischoff H, Bömer B, Fey P, Grosser R, Hübsch W, Lange W, Lautz J, Schmidt D (1993) 2te Eur Med Chem Conf (31. März bis 4. April, Bad Nauheim); zit. nach Lit. 2
Ness GC, Zhao Z, Lopez D (1996) Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys 325:242–248
Gargouri Y, Pieroni G, Riviere C, Sauniere JF, Lowe PA, Sarda L, Verger R (1986) Gastroenterology 91:919–925
Swan JS, Hoffmann MM, Lord MK, Poechmann JL (1992) Biochem J 283:119–122
Walde P, Luisi PL (1989) Biochem 28:3353–3360
Möller H (1979) Dtsch Apoth Ztg 124:2279–2286
Bergmeyer HU (1983) Methods of Enzymatic Analysis, 3.Aufl., Bd.2, Verlag Chemie, Weinheim, S. 236
Junge W (1984) Lipasen in: Bergmeyer HU (Hrsg), 3. Aufl., Bd.4, Verlag Chemie, Weinheim, S. 15–25
Pointner H, Flegel U (1975) Arzneim Forsch 25:1833–1835
Unterberg C, Spencer F (1986) Fette Seifen Anstrichmittel 88:561–564
Ammann R (1979) Internist 20:392–398
DiMagno EP, Go VLW, Summerskill WHJ (1973) N Engl J Med 288:813–815
Löser Chr, Fölsch UR (1991) Leber Magen Darm, Heft 2:56–65
Abiodun P, Tolckmitt W (1982) Der Kinderarzt 13:1987–1994
Brackmann P, Rüther HG (1984) Fortschr med 44:102, 1143/1165-145/167
Fölsch UR (1989) Dtsch Ärztebl 86:792–793
Drugs Fut (1994) 19(9):841-844, zit. nach Savage DS, Sleig T, Carlyte IG; AU 8814570, EP 297150, JP 88277693, US 4894369
Mirakhur RK (1992) Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use. Drugs 44:182–199
Mellinghoff H (1994) Moderne Muskelrelaxanzien und ihre klinische Anwendung. Anaesthesist 43:270–282
Bevan DT (1994) Newer neuromuscular blocking agents. Pharmacol Toxicol 74:3–9
Caldwell JE (1995) New skeletal muscle relaxants. Int Anesthesiol Clin 33:39–60
Hunter JM (1995) New neuromuscular blocking drugs. N Engl. J Med 332:1691–1699
Appadu BL, Lambert DG (1994) Studies on the interaction of steroidal neuromuscular blocking drugs with cardiac muscarine receptors. Br J Anaesth 72:86–88
Naguib M, Samarkandi AH, Bakhamees HS, Magboul MA, el Bakry AK (1995) Histamine-release and haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine. Br J Anaesth 75:588–592
McCoy EP, Mirakhur RK, Maddineni VR, Wierda JM, Proost JH (1996) Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. Br J Anaesth 76:29–33
Sparr HJ, Khuenl-Brady KS, Eriksson LI (1994) Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. Eur J Anaesthesiol Suppl 9:63–65
Mar 31, S.1525
Diefenbach C (1997) Mivacurium und Cisatracurium. Arzneimitteltherapie 15:65–68
Cooper RA, Mirakhur RK, Wierda JM, Maddineni VR (1995) Pharmacokinetics of rocuronium bromide in patients with and without renal failure. Eur J Anaesthesiol Suppl 11:43–44
van den Broek L, Wierda JM, Smeulers NJ, van Santen GJ, Leclercq MG, Hennis PJ (1994) Clinical pharmacology of rocuronium (Org 9426): study of the time course of action, dose requirement, reversibility, and pharmacokinetics. J Clin Anesth 6:288–296
Khalil M, D’Honneur G, Duvaldestin P, Slavor V (1994) Pharmacokinetics and pharmacodynamics in patients with cirrhosis. Anaesthesiology 80:1241–1247
Bevan DR (1994) Rocuronium bromide and organ function. Eur J Anaesthesiol Suppl 9:87–91
Mirakhur RK (1995) Dose-response and time-course of action of rocuronium bromide. Eur J Anaesthesiol Suppl 11:23–25
Mayer M, Doenicke A, Hofmann A, Peter K (1992) Onset and recovery of rocuronium (Org 9426) and vecuronium under enflurane anaesthesia. Br J Anaesth 69:511–512
Khuenl-Brady KS (1993) Rocuronium, das „ideale“ nicht depolarisierende Muskelrelaxans? Anaesthesist 42:757–765
Scheiber G, Ribeiro FC, Marichal A, Bredendiek M, Renzing K (1996) Intubating conditions and onset of action after rocuronium, vecuronium, and atracurium in young children. Anesth Analg 83:320–324
Drugs Fut (1992) 17:791-795
McCague F, Jarman M, Rowland MG, Mann J, Thickitt CP, Clissold DW, Neidle S, Webster G (1989) J Chem Soc Perkin Trans I:196
Boss AM, Clissold DW, Mann J, Markson AJ, Thickitt CP (1989) Tetrahedron 45:6011
Foster AB, Jarman M, Leung C-S, Rowlands MG, Taylor G., Plevey RG, Sampson P (1985) J Med Chem 28:200–204
Lonning PE, Dowsett M, Powles TJ (1990) Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 35(3–4):355–366
Dowsett M (1990) Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. J Steroid Biochem Mol Biol 37(6):1037–1041
Hynes BP, Jarman M, Dowsett M, Metha A, Lonning PE, Griggs LJ, Jones A, Powles T Stein R, Coombes RC (1991) Pharmacokineties and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemother Pharmacol 27(5):367–372
Dowsett M, MacNeill F, Metha A, Newton C, Haynes B, Jones A, Jarman M, Lonning P, Powles TJ, Coombes RC (1991) Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione (‘pyridoglutethimide’) in postmenopausal breast cancer patients. Br J Cancer 64(5):887–894
Drugs Fut (1993) 18(1):89-89
Drugs Fut (1994) 19(1):83-85
Krause W, Kühne G (1992) J Chromatogr Biomed Appl 573(2):303–308
Araki T, Kato H, Shuto K, et al (1997) Age-realted changes in (3H)nimodipine and (3H)rolipram binding in the rat brain. J Pharm Pharmacol 49:310–314
Block F, Tondar A, Schmidt W, et al. (1997) Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats. Neuroreport 8:3829–3832
Christensen SB, Guider A, Forster CJ, et al. (1998) 1,4-Cyclohecanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J Med Chem 41:821–835
Dowling RMB, Johnson M, Cole PJ, et al. (1997) The effect of rolipram, a type IV phosphodiesterase inhibitor, on Pseudomonas aeruginosa infection of respiratory mucosa. J Pharmacol Exp Ther 282:1565–1571
Egawa T, Mishima K, Matsumoto Y, et al. (1997) Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn J Pharmacol 75:275–281
Hadcraft J, Hill S, Humpel M, et al. (1990) Investigations on the percutaneous absorption of the antidepressant rolipram in vitro and in vivo. Pharm Res 7:1307–1312
Hasko G, Szabo C, Nemeth ZH, et al. (1998) Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 dependent. Eur J Immunol 28:468–472
Imanishi T, Sawa A, Ichimaru Y, et al. (1997) Ameliorating effects of rolipram on experimentally induced impariment of learning and memory in rodents. Eur J Pharmacol 321:273–278
Krause W, Kuhne G, Matthes H (1989) Pharmacokinetics of the antidepressant rolipram in healthy volunteers. Xenobiotica 19:683–692
Krause W, Kuhne G, Sauerbrey N (1990) Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers. Eur J Pharmacol 38:71–75
Krause W, Kuhne G (1993) Biotransformation of the antidepressant D,L-rolipram. II. Metabolite patterns in man, rat, rabbit, rhesus and cynomolgus monkey. Xenobiotica 23:1277–1288
Liang L, Beshay E, Prud’homme GJ (1998) The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 47:570–575
Navarro J, Punzon C, Jimenez JL, et al. (1998) Inhibition of phosphodiesterase type IV supresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappa B and NFAT. J Virol 72:4712–4720
Nyman U, Mussener A, Larsson E, et al. (1997) Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram. Clin Exp Immunol 108:415–419
Pfeffer M, Sauerbrey N, Windt-Hanke F, et al. (1990) In-vitro and in-vivo characterisation of two sustained release formulations for the antidepressant rolipram. Arzneimittelf 40:1191–1194
Ross SE, Williams RO, Mason LJ, et al. (1997) Supression of TNF-alpha expression, inhibition of Th 1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 159:6253–6259
Saito T, Ozawa H, Kamata H, et al. (1998) Differential effects of chronic administration of the antidepressants amitriptyline and rolipram on adenylyl cyclase activity. Nihon Shinkei Seishin Yakurigaku Zasshi 18:23–25
Shichijo M, Shimizu Y, Hiramatsu K, et al. (1997) Cyclic AMP-elevating agents inhibit mice-antigen-induced IL-4 and IL-13 relase from basophil-enriched leukocyte preparation. Int Arch Allerg Immunol 114:348–353
Wagner RS, Smith CJ, Taylor AM, et al (1997) Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 282:1650–1657
Yoshimura T, Nagao T, Nakao T, et al (1998) Modulation of Th1-and Th2-like cytokine production from mitogenstimulated human peripheral blood mononuclear cells by phosphodiesterase inhibitors. Gen Pharmacol 30:175–180
Drugs Fut (1989) 14:432-437
Moroi R, Yamazaki K, Hirota T, Watanabe S, Kataoka K, Ichinose M (1988) Arzneim-Forsch 38:953–959
MI 12
Akasaki M, Masayasu H, Tsukada W et al. (1988) Specific binding sites of muroctasin on murine macrophages. Arznf 38:978–980
Azuma I (1992) Development of the cytokine inducer romurtide: experimental studies and clinical application. Trends Pharmacol Sci 13:425–428
Azuma I, Ishihara C, Iida J et al. (1992) Stimulation of host-defense mechanism with synthetic adjuvants and re-combinant cytokines against viral infection in mice. Adv Exp Med Biol 319:253–263
Eizuru Y, Nakagawa N, Hamasuna R et al. (1992) Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection. Nat Immun 11:225–236
Furuse K et al. (1989) Prog Med 9:631–649 zit. nach2
Furuse K, Sakuma A (1989) Activation of the cytokine network by muroctasin as a remedy for leukopenia and thrombopenia. Arznf 39:915–917
Hiraoka A, Masaoka T, Satoh T et al. (1988) Hematological response of the new synthetic muramyl dipeptide derivative muroctasin after chemotherapy in patients with malignant lymphoma. A randomized crossover trial. Arznf 38:1499–1501
Ishihara N, Kanazawa R, Sasaki S et al. (1988) Phase I study and clinical pharmacological study of muroctasin. Arznf 38:1043–1069
Matsubayashi K, Takegoshi T (1988) Biotransformation of muroctasin in mice. Arznf 38:1015–1018
Nakajima R, Yshida Y, Akahane K et al. (1991) Stimulatory effect of romurtide on hematopoiesis in monkeys. Arznf 41:60–65
Nakajima R, Namba K, Ishida Y et al. (1992) Synergistic effect of romurtide with ampicillin against pneumococcal pneumonia in mice. Chemother 38:238–250
Namba K, Nakajima R, Otani T et al. (1996) Oral application of romurtide, a synthetic muramyl dipeptide derivative, stimulates nonspecific resistance to microbial dipeptide derivative, stimulates nonspecific resistance to microbial infections and hematopoiesis in mice. Vaccine 14:1149–1153
Namba K, Nitanai H, Otani T et al. (1996) Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model. Vaccine 14:1322–1326
Namba K, Yamamura E, Nitanai H et al. (1997) Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression. Vaccine 15:405–413
Osada Y, Otani T, Sato M et al. (1982) Polymorphonuclear leukocyte activation by a synthetic muramyl dipeptide analog. Infect Immun 38:848–854
Suzuki K, Torii K, Hida S et al. (1994) Differences in interleukin 1 (IL-1), IL-6, tumor necrosis factor and IL-1 receptor antagonist production by human monocytes stimulated with muramyl dipeptide (MDP) and its stearoyl derivative, romurtide. Immunopharmacol 28:31–38
Tatara O, Nakahama C, Niki Y (1992) Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice. Antimicrob Ag Chemother 36:167–171
Tsubura E, Nomura T, Niitani H et al. (1988) Restorative activity of muroctasin on leukopenia associated with anti-cancer treatment. Arznf 38:1070–1074
Yano K, Matsuoka H, Seo Y et al. (1995) Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer. Anticancer Res 15:2883–2887
Yoo YC, Sakai I, Sato K et al. (1994) MDP-Lys (L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice. Vaccine 12:175–160
Drugs Fut (1989) 14(8):767-771
Thuresson Af Ekenstam B, Bovin C (Astra Lakemedel AB), L-N-Propylpipecolic acid-2,6-xylidid. US 4695576; zit. nach1
Thuresson Af Ekenstam B, Bovin C (Apothekernes laboratorium for specialpraeparater A (S). L-N-n-Propylpipecolic acid-2,6-xylidid and method for preparing the same. AU 8317796; EP 151110; JP 855020554; WO 8500599; zit. nach1
Stahlberg C (1987) Synthesis of carbon-14 labelled ropivacaine, a local anaesthetic. J Label Compound Radiopharm 24(5):529–534; zit. nach1
Sandberg RV (Astra Läkemedel Aktiebolag) S-(-)-1-Propyl-2′,6′-pipecoloxylidide hydrochloride monohydrate, process for its preparation and pharmaceutical preparation containing it. EP 239710; zit. nach1
Niesei HC, Kaiser H, Ellingsfeld T (1990) Ropivacain — ein neues Lokalanästhetikum mit spezifischen Eigenschaften. Reg Anaesth 13:54–56
Hickey R, Blanchard J, Hoffman J, Sjovall J, Ramamurthy S (1990) Plasma concentration of ropivacaine given with or without epinephrine for brachia plexus block. Can J Anaesth 8:878–882
March CR, Hardy AJ (1991) Ropivacaine: a new local anaesthetic agent. Br J Hosp Med 45:94–95
Finucane BT (1990) Ropivacaine — a worthy replacement for bupivacaine? Can J Anaesth 37:722–725
Concepcion M, Arthur GR, Steele SM, BaderAM, Covino BG (1990) A new local anaesthetic, ropivacaine. Its epidural effect in humans. Anesth Analg 70:80–85
Zaric D, Axelsson K, Nydahl PA, Philipsson L, Larsson P, Jansson JR (1991) Sensory and motor blockade during epidural analgesia with 1 %, 0,75 %, and 0,5 % ropivacaine — a double blind study. Anesth Analg 72:509–515
Markham A, Faulds D, Abernethy DR, (1996) Ropivacaine. A review of its pharmacology and therapeutic use in regional anaesthesia. Drugs 52:429–449
Lee A, Fagan D, Lamont M, Tucker GT, Halldin M, Scott DB (1989) Disposition kinetics of ropivacaine in humans. Anesth Analg 69:736–738
Kopacz DJ, Emanuelsson BM, Thomson GE, Carpenter RL, Stephenson CA (1994) Pharmacokinetics of ropivacaine and bupivacaine in healthy male volunteers. Anesthesiology 81:1139–1148
Katz JA, Bridenbough PO, Knarr DC, Helton SH, Denson DD (1990) Pharmacodynamics and pharmacokinetics of epidural ropivacaine in humans. Anesth Analg 70:16–21
Morrison LMM, Emanuelsson BM, McClure JH, Pollok AJ, McKeown DW, Brockway M, Jozwiak H, Wildsmith JA (1994) Efficacy and kinetics of extradural ropivacaine: comparison with bupivacaine. Br J Anaesth 72:164–169
Brockway MS, Bannister J, McClure JH, McKeown D, Wildsmith JA (1991) Comparison of extradural ropivacaine and bupivacaine. Br J Anesth 66:31–37
Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y (1995) Metabolism of a new local anaesthetic, ropivacaine, by human hepatic cytochrome p450. Anesteshiology 82:214–220
deJong RH (1995) Gaston labat lecture. Ropivacaine. White knight or dark horse? Reg Anesth 20:474–481
Hickey R, Hoffman J, Ramamurthy S (1991) A comparison of ropivacaine 0,5 % and bupivacaine 0,5 % for brachial plexus block. Anesthesiology 74:639–642
van Kleef JW, Veering BT, Burm AGL (1994) Spinal anesthesia with ropivacaine: a double-blind study on the efficacy and safety of 0,5 % and 0,75 % solutions in patients undergoing minor lower limb surgery. Anesth Analg 78:1125–1130
Badner NH, Reid D, Sullivan P, Ganapathy S, Crosby ET, McKenna J, Lui A (1996) Continuous epidural infusion of ropivacaine for the prevention of postoperative pain after major orthopaedic surgery: a dose-finding study. Can J Anesth 43:17–22
Stienstra R, Jonker TA, Bourdrez P, Kuijpers JC, van Kleef JW, Lundberg U (1995) Ropivacaine 0,25 % versus bupivacaine 0,25 % for continuous epidural analgesia in labor: a double-blind comparison. Anesth Analg 80:285–289
Kerkamp HEM, Gielen MJM (1991) Cardiovascular effects of local anaesthetics. Anaesthesia 46:361–365
Wolff AP, Hasselstroem L, Kerkkamp HE, Gielen MJ (1990) Extradural ropivacaine and bupivacaine in hip surgery. Br J Anesthesia 64:67–71 1. Drug Fut (1995) 20(1):19-23
Abramsky O, Lehmann D, Karassis D (1996) Immunomodulation with linomide: possible novel therapy for multiple sclerosis. Mult Scler 2:206–210
Anderson O, Lycke J, Tollesson PO et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurol 47:895–900
Borgstrom P, Torres Filho IP, Vajkoczy P et al. (1994) The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol 34:280–286
Diab A, Michael L, Wahren B et al. (1998) Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. J Neuroimmunol 85:146–154
Ekstrom PA, Hedlund G, Karlsson J et al. (1998) The immune modulator linomide prevents neuronal death in injured peripheral nerves of the mouse. Neuroreport 9:1337–1341
Eralinna JP, Roytta M, Hukkanen V et al. (1998) Selective downregulation of Th1 response by linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice. J Neuroimmunol 88:165–176
Gonzalo JA, Gonzalez-Garcia A, Kalland T et al. (1993) Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol 23:2372–2374
Gonzalo JA, Gonzalez-Garcia A, Kalland T et al. (1994) Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur J Immunol 24:48–52
Gross DJ, Weiss L, Reibstein I et al. (1998) Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment. Endocrinol 139:2369–2374
Joseph IB, Isaacs JT (1996) The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis. Prostate 29:183–190
Karussis DM, Meiner Z, Lehmann D et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resoncance imaging evaluation. Neurol 47:341–346
Lehmann D, Karassis D, Mizrachi-Koll R et al. (1997) Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RO+ cells. Clin Immunol Immunopath 85:202–209
Lepisto J, Laato M, Niinikoski J et al. (1994) Stimulation of wound healing by the immunomodulator LS-2616 (linomide) World J Surg 18:818–820 (Diskuss.)
Rosenfeld CS, Zeigler ZR, Shadduck RK et al. (1997) Phase II study of roquinimex in myelodysplastic syndrome. Am J Clin Oncol 20:189–192
Shoenfeld Y (1994) Immunosupppression of experimental systemic lupus erythematosus and antiphospholipid syndrome. Transpl Proc 26:3211–3213
Slavin S, Gross D, Weiss (1995) Prevention and treatment of type I diabetes in NOD mice by linomide. Transpl Proc 27:3240
Tian WZ, Navikas V, Matusevicius D et al. (1998) Linomide (roquinimex) affects the balance between pro-and anti-inflammatory cytokines in vitro in multiple slcerosis. Acta Neurol Scand 98:94–101
Wanders A, Larsson E, Gergin B et al. (1989) Abolition of the effect of cyclosporine on rat cardiac allograft rejection by the new immunomodulator LS-2616 (linomide). Transpl 47:216–217
Xiao BG, Bail XF, Zhang GX et al. (1998) Linomide-mediated protection of oligodendrocytes is associated with inhibition of nitric oxide production and IL-1beta expression in Lewis rat glial cells. Neurosci Lett 249:17–20
Zandman-Goddard G, George J, Levy Y et al. (1996) Modulation of experimental systemic lupus erythematosus with linomide. Lupus 5:328–333
Zhang GX, Yu LY, Shi FD et al. (1998) Cytokine profiles of experimental autoimmune myasthenia gravis after treatment by the synthetic immunomodulator linomide. Ann N Y Acad Sci 841:580–583
Ziche M, Donnini S, Morbidelli L et al. (1998) Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants. Brit J Cancer 77:1123–1129
Hausberg HH, Koppe V, Poetsch E, Saiko O, Seyfried C (Merck Patent GmbH) EP 007399, zit. nach Lit. 2
Robinson C, Castañer J (1995) Drugs Fut 20:1228–1232
Hausberg HH, Böttcher H, Seyfried C, Bergmann R (Merck Patent GmbH) EP 166183, JP 85258117, US 4711893, DE 3419935, zit. nach Lit. 2
Böttcher H, Barnickel G, Hausberg HH, Haase AF, Seyfried CA, Eiermann V (1992) J Med Chem 35:4020–4026
Robinson C (1995) Drugs Fut 20:148–152
Barone AD, Ghrayeb J, Hammerling U, Zucker MB, Thorbecke GJ (1988) J Biol Chem 263:8710–8715
Hermodson M, Schmer G, Kurachi K (1977) J Biol Chem 252:6276–6279
Maione TE, Gray GS, Petra J, Hunt AJ et al. (1990) Science 247:77–79
Zhang X, Chen L, Bancroft DP (1994) Biochem 33:8361–8366
Cecchetti V, Fravolini A, Friguelli R, Mascellani G, Pagella P, Palmioli M, Segre G, Terni P (1987) J Med Chem 30:465–473
Carlucci G, Mazzeo P, Fanini D, Palumbo D (1991) Ther Drug Monit 13:448
Vree TB, Vandenbiggelaarmartea M, Peeters A, Imbimbo BP (1992) J Chromatogr Biomed Appl 573:168
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
von Bruchhausen, F. et al. (1999). R. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58388-9_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-58388-9_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63569-4
Online ISBN: 978-3-642-58388-9
eBook Packages: Springer Book Archive